Our study the NSCLC harbors EGFR-mutation with Conmana combined with thalidomide as
first-line treatment, is expected to improve further EGFR-Tyrosine kinase inhibitors (TKI)
response rate (ORR), prolong time to progression (PFS), improve patient survival.